TY - JOUR
T1 - sGC stimulators
T2 - Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
AU - Benza, Raymond
AU - Mathai, Stephen
AU - Nathan, Steven D.
N1 - Funding Information:
Katrina Rodies, CRNP, provided medical writing assistance for the authors during preparation of the manuscript. Additional editorial support and formatting assistance was provided by Adelphi Communications, LLC. Writing assistance, editorial support, and article processing fees were funded by Bayer HealthCare.
Publisher Copyright:
© 2016
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Pulmonary hypertension (PH) is a chronic cardiopulmonary disorder that if left untreated, progresses rapidly and is ultimately fatal. The World Health Organization (WHO) has classified PH into 5 distinct groups according to pathophysiology, hemodynamic characteristics, and clinical presentation. Dysfunction in the nitric oxide (NO) pathway plays a key role in the pulmonary hypertension disease process, including in WHO Groups 2 and 3 PH. PH is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) pathway, which reduces cGMP production. cGMP regulates vascular tone, cellular proliferation, inflammation, and fibrosis and its depletion can lead to a variety of abnormalities, including pulmonary vasoconstriction, impaired vascular remodeling, and in situ thrombosis. This review will examine a novel class of drugs called sGC stimulators which directly stimulate sGC independently of NO, leading to increased production of cGMP.
AB - Pulmonary hypertension (PH) is a chronic cardiopulmonary disorder that if left untreated, progresses rapidly and is ultimately fatal. The World Health Organization (WHO) has classified PH into 5 distinct groups according to pathophysiology, hemodynamic characteristics, and clinical presentation. Dysfunction in the nitric oxide (NO) pathway plays a key role in the pulmonary hypertension disease process, including in WHO Groups 2 and 3 PH. PH is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) pathway, which reduces cGMP production. cGMP regulates vascular tone, cellular proliferation, inflammation, and fibrosis and its depletion can lead to a variety of abnormalities, including pulmonary vasoconstriction, impaired vascular remodeling, and in situ thrombosis. This review will examine a novel class of drugs called sGC stimulators which directly stimulate sGC independently of NO, leading to increased production of cGMP.
KW - NO-sGC-cGMP pathway
KW - Pulmonary arterial hypertension
KW - Riociguat
KW - sGC stimulators
UR - http://www.scopus.com/inward/record.url?scp=85007227371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007227371&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2016.11.010
DO - 10.1016/j.rmed.2016.11.010
M3 - Article
C2 - 27890470
AN - SCOPUS:85007227371
SN - 0954-6111
VL - 122
SP - S28-S34
JO - Respiratory Medicine
JF - Respiratory Medicine
ER -